Reuters reported on 15 April that the cybersecurity company BrandShield has shut down over 250 websites selling counterfeit versions of popular drugs used for weight loss and diabetes treatment within the GLP-1 class.
The company closed 279 pharmacy websites in 2023 for selling medications intended for metabolic conditions, with over 90% related to GLP-1 medicines.
GLP-1 drugs such as Novo Nordisk’s Ozempic and Wegovy, as well as Eli Lilly’s Mounjaro and Zepbound, were initially developed for type 2 diabetes but have also been found to curb food cravings and slow down stomach emptying, leading to weight loss in patients.
In 2023, BrandShield removed 3,968 listings for fake drugs from social media platforms, with almost 60% originating from Facebook.